{"title_page": "Endothelin", "text_new": "{{Pfam_box \n| Symbol = Endothelin \n| Name = Endothelin family \n| image = 1EDN human endothelin1 02.png\n| width = \n| caption = \n| Pfam= PF00322\n| InterPro= IPR001928\n| SMART= \n| Prosite = PDOC00243\n| SCOP = 1edp\n| TCDB = \n| OPM family= 147\n| OPM protein= 3cmh\n| PDB=   \n}} \n{{infobox protein \n| Name = [[Endothelin 1]] \n| caption = \n| image = | width = \n| HGNCid = 3176 \n| Symbol = [[EDN1]] \n| AltSymbols = \n| EntrezGene = 1906 \n| OMIM = 131240 \n| RefSeq = NM_001955 \n| UniProt = P05305 \n| PDB = \n| ECnumber = \n| Chromosome = 6 \n| Arm = p \n| Band = 23 \n| LocusSupplementaryData = -p24 }}\n{{infobox protein\n| Name = [[Endothelin 2]]\n| image = \n| width = \n| caption =\n| Symbol = [[Endothelin 2|EDN2]]\n| AltSymbols =\n| ATC_prefix=\n| ATC_suffix=\n| ATC_supplemental=\n| CAS_number=\n| CAS_supplemental=\n| DrugBank=\n| EntrezGene = 1907\n| HGNCid =3177\n| OMIM = 131241\n| PDB =\n| RefSeq = NM_001956\n| UniProt = P20800\n| ECnumber = \n| Chromosome = 1\n| Arm = p\n| Band = 34\n| LocusSupplementaryData = \n}}\n{{infobox protein\n| Name = [[Endothelin 3]]\n| image = \n| width = \n| caption =\n| Symbol = [[EDN3]]\n| AltSymbols =\n| ATC_prefix=\n| ATC_suffix=\n| ATC_supplemental=\n| CAS_number=\n| CAS_supplemental=\n| DrugBank=\n| EntrezGene = \n| HGNCid =3178\n| OMIM = 131242\n| PDB =\n| RefSeq = NM_000114\n| UniProt = P14138\n| ECnumber = \n| Chromosome = 20\n| Arm = q\n| Band = 13.2\n| LocusSupplementaryData = -q13.3\n}}\n'''Endothelins''' are peptides with [[receptor (biochemistry)|receptor]]s and effects in many body organs.<ref name=\"pr\">{{cite journal | vauthors = Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ | display-authors = 6 | title = Endothelin | journal = Pharmacological Reviews | volume = 68 | issue = 2 | pages = 357\u2013418 | date = April 2016 | pmid = 26956245 | pmc = 4815360 | doi = 10.1124/pr.115.011833 }}</ref><ref name=\"cmls\">{{cite journal | vauthors = Kawanabe Y, Nauli SM | title = Endothelin | journal = Cellular and Molecular Life Sciences | volume = 68 | issue = 2 | pages = 195\u2013203 | date = January 2011 | pmid = 20848158 | pmc = 3141212 | doi = 10.1007/s00018-010-0518-0 }}</ref><ref name=\"arpt\">{{cite journal | vauthors = Kedzierski RM, Yanagisawa M | title = Endothelin system: the double-edged sword in health and disease | journal = Annual Review of Pharmacology and Toxicology | volume = 41 | pages = 851\u201376 | year = 2001 | pmid = 11264479 | doi = 10.1146/annurev.pharmtox.41.1.851 }}</ref>  Endothelin constricts blood vessels and raises blood pressure. The endothelins are normally kept in balance by other mechanisms, but when [[gene expression|overexpressed]], they contribute to high blood pressure ([[hypertension]]), [[heart disease]], and potentially other diseases.<ref name=pr/><ref>{{cite journal | vauthors = Maguire JJ, Davenport AP | title = Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12 | journal = British Journal of Pharmacology | volume = 171 | issue = 24 | pages = 5555\u201372 | date = December 2014 | pmid = 25131455 | pmc = 4290702 | doi = 10.1111/bph.12874 }}</ref>\n\nEndothelins are 21-[[amino acid]] [[vasoconstriction|vasoconstricting]] [[peptide]]s produced primarily in the [[endothelium]] having a key role in [[smooth muscle|vascular homeostasis]]. Endothelins are implicated in vascular diseases of several organ systems, including the heart, lungs, kidneys, and brain.<ref name=\"pmid11984741\">{{cite journal | vauthors = Agapitov AV, Haynes WG | title = Role of endothelin in cardiovascular disease | journal = Journal of the Renin-Angiotensin-Aldosterone System | volume = 3 | issue = 1 | pages = 1\u201315 | date = March 2002 | pmid = 11984741 | doi = 10.3317/jraas.2002.001 }}</ref><ref name=\"pmid16529555\">{{cite journal | vauthors = Schinelli S | title = Pharmacology and physiopathology of the brain endothelin system: an overview | journal = Current Medicinal Chemistry | volume = 13 | issue = 6 | pages = 627\u201338 | year = 2006 | pmid = 16529555 | doi = 10.2174/092986706776055652 }}</ref> As of 2018, endothelins remain under extensive [[basic research|basic]] and [[clinical research]] to define their roles in several organ systems.<ref name=pr/><ref>{{cite journal | vauthors = Kuang HY, Wu YH, Yi QJ, Tian J, Wu C, Shou WN, Lu TW | title = The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis | journal = Medicine | volume = 97 | issue = 10 | pages = e0075 | date = March 2018 | pmid = 29517668 | pmc = 5882424 | doi = 10.1097/MD.0000000000010075 }}</ref><ref>{{cite journal | vauthors = Iljazi A, Ayata C, Ashina M, Hougaard A | title = The Role of Endothelin in the Pathophysiology of Migraine-a Systematic Review | journal = Current Pain and Headache Reports | volume = 22 | issue = 4 | pages = 27 | date = March 2018 | pmid = 29557064 | doi = 10.1007/s11916-018-0682-8 }}</ref><ref>{{cite journal | vauthors = Lu YP, Hasan AA, Zeng S, Hocher B | title = Plasma ET-1 Concentrations Are Elevated in Pregnant Women with Hypertension -Meta-Analysis of Clinical Studies | journal = Kidney & Blood Pressure Research | volume = 42 | issue = 4 | pages = 654\u2013663 | year = 2017 | pmid = 29212079 | doi = 10.1159/000482004 }}</ref>\n\n==Etymology==\nEndothelins derived the name from their isolation in cultured [[endothelial cell]]s.<ref name=pr/><ref name=mc>{{cite book|first1=Ronald F|last1=Tuma|first2=Walter N|last2=Dur\u00e1n|first3=Klaus|last3=Ley|name-list-format=vanc|title=Microcirculation|year=2008|publisher=Elsevier/Academic Press|location=Amsterdam|isbn=978-0-12-374530-9|pages=[https://archive.org/details/microcirculation0000unse/page/305 305\u2013307]|edition=2nd|url=https://archive.org/details/microcirculation0000unse/page/305}}</ref>\n\n== Isoforms ==\n\nThere are three [[isoform]]s of the peptide (identified as ET-1, -2, -3), each encoded by a separate gene, with varying regions of expression and binding to at least four known [[endothelin receptor]]s, ET<sub>A</sub>, ET<sub>B1</sub>, ET<sub>B2</sub> and ET<sub>C</sub>.<ref name=pr/><ref name=\"boron\">{{cite book| first1=Walter F. |last1=Boron|first2= Emile L.|last2= Boulpaep | name-list-format = vanc |title=Medical physiology a cellular and molecular approach|year=2009|publisher=Saunders/Elsevier|location=Philadelphia, PA|isbn=978-1-4377-2017-4|pages=480|edition=2nd International}}</ref>\n\nThe human [[gene]]s for endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3) are located on [[chromosome]]s 6, 1, and 20, respectively.<ref name=cmls/>\n\n== Mechanism of action and function ==\n\nEndothelin functions through activation of two [[G protein]]-coupled receptors, endothelin<sub>A</sub> and endothelin<sub>B</sub> receptor (ETA and ETB, respectively).<ref name=cmls/> These two subtypes of endothelin receptor are distinguished in the laboratory by the order of their affinity for the three endothelin peptides: the ETA receptor is selective for ET-1, whereas the ETB receptor has the same affinity for all three ET peptides.<ref name=cmls/> The two types of ET receptor are distributed across diverse cells and [[organ (anatomy)|organs]], but with different levels of expression and activity, indicating a multiple-organ ET system.<ref name=cmls/>\n\nEndothelin-1 is the most powerful [[endogenous]] chemical affecting vascular tone across organ systems.<ref name=cmls/><ref name=\"miy\">{{cite journal | vauthors = Miyauchi T, Sakai S | title = Endothelin and the heart in health and diseases | journal = Peptides | volume = 111 | pages = 77\u201388 | date = January 2019 | pmid = 30352269 | doi = 10.1016/j.peptides.2018.10.002 }}</ref> Secretion of endothelin-1 from the vascular [[endothelium]] signals vasoconstriction and influences local cellular growth and survival.<ref name=miy/>  ET-1 has been implicated in the development and progression of several [[cardiovascular disease]]s, such as [[atherosclerosis]] and [[hypertension]].<ref name=miy/> Endothelin also has roles in [[mitogenesis]], cell survival, [[angiogenesis]], bone growth, [[nociceptor]] function, and cancer onset mechanisms.<ref name=cmls/> Clinically, anti-ET drugs are used to treat [[pulmonary arterial hypertension]].<ref name=cmls/><ref name=miy/>\n\n==Physiological effects==\nEndothelins are the most potent vasoconstrictors known.<ref name=pr/><ref name=craig>{{cite book|first1=Charles R|last1=Craig|first2= Robert E|last2= Stitzel | name-list-format = vanc |title=Modern pharmacology with clinical applications|year=2004|publisher=Lippincott Williams & Wilkins|location=Philadelphia|isbn=978-0-7817-3762-3|pages=215|edition=6th}}</ref> Overproduction of endothelin in the lungs may cause [[pulmonary hypertension]], which was treatable in preliminary research by [[bosentan]], [[sitaxentan]] or [[ambrisentan]].<ref name=pr/>\n\nEndothelins have involvement in cardiovascular function, fluid-[[electrolyte]] [[homeostasis]], and neuronal mechanisms across diverse cell types.<ref name=pr/> Endothelin receptors are present in the three [[pituitary gland|pituitary lobes]]<ref>{{cite journal | vauthors = Lange M, Pagotto U, Renner U, Arzberger T, Oeckler R, Stalla GK | title = The role of endothelins in the regulation of pituitary function | journal = Experimental and Clinical Endocrinology & Diabetes | volume = 110 | issue = 3 | pages = 103\u201312 | date = May 2002 | pmid = 12012269 | doi = 10.1055/s-2002-29086 }}</ref> which display increased metabolic activity when exposed to endothelin-1 in the blood or ventricular system.<ref>{{cite journal | vauthors = Gross PM, Wainman DS, Espinosa FJ | title = Differentiated metabolic stimulation of rat pituitary lobes by peripheral and central endothelin-1 | journal = Endocrinology | volume = 129 | issue = 2 | pages = 1110\u20132 | date = August 1991 | pmid = 1855455 | doi = 10.1210/endo-129-2-1110 }}</ref>\n\nET-1 contributes to the vascular dysfunction associated with cardiovascular disease, particularly [[atherosclerosis]] and [[hypertension]].<ref name=\"pmid17617392\">{{cite journal | vauthors = B\u00f6hm F, Pernow J | title = The importance of endothelin-1 for vascular dysfunction in cardiovascular disease | journal = Cardiovascular Research | volume = 76 | issue = 1 | pages = 8\u201318 | date = October 2007 | pmid = 17617392 | doi = 10.1016/j.cardiores.2007.06.004 | url = https://pdfs.semanticscholar.org/0919/6e83c2860201c9a761b228777799c1c0b8aa.pdf }}</ref> The ET<sub>A</sub> receptor for ET-1 is primarily located on vascular smooth muscle cells, mediating vasoconstriction, whereas the ET<sub>B</sub> receptor for ET-1 is primarily located on endothelial cells, causing vasodilation due to [[nitric oxide]] release.<ref name=\"pmid17617392\" />\n\nThe binding of [[platelet]]s to the [[endothelium|endothelial cell]] receptor [[OLR1|LOX-1]] causes a release of  endothelin, which induces [[endothelial dysfunction]].<ref name=\"pmid10618423 \">{{cite journal | vauthors = Kakutani M, Masaki T, Sawamura T | title = A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 97 | issue = 1 | pages = 360\u20134 | date = January 2000 | pmid = 10618423 | pmc = 26668 | doi = 10.1016/j.biochi.2016.10.010 | bibcode = 2000PNAS...97..360K | url = http://www.pnas.org/content/97/1/360.long }}</ref>\n\n== Clinical significance ==\n\nThe ubiquitous distribution of endothelin peptides and receptors implicates involvement in a wide variety of physiological and pathological processes among different [[organ (anatomy)|organ systems]].<ref name=pr/> Among numerous diseases potentially occurring from endothelin dysregulation are:\n\n* several types of [[cancer]]<ref name=cmls/><ref name=\"pmid18325824\">{{cite journal | vauthors = Bagnato A, Rosan\u00f2 L | title = The endothelin axis in cancer | journal = The International Journal of Biochemistry & Cell Biology | volume = 40 | issue = 8 | pages = 1443\u201351 | year = 2008 | pmid = 18325824 | doi = 10.1016/j.biocel.2008.01.022 }}</ref>\n* [[Cerebrum|cerebral]] [[vasospasm]] following [[subarachnoid hemorrhage]]<ref name=\"pmid17479073\">{{cite journal | vauthors = Macdonald RL, Pluta RM, Zhang JH | title = Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution | journal = Nature Clinical Practice. Neurology | volume = 3 | issue = 5 | pages = 256\u201363 | date = May 2007 | pmid = 17479073 | doi = 10.1038/ncpneuro0490 }}</ref>\n* [[arterial hypertension]], [[pulmonary hypertension]], and other [[cardiovascular]] disorders<ref name=cmls/>\n* [[pain]] mediation<ref name=\"pmid15664691\">{{cite journal | vauthors = Hasue F, Kuwaki T, Kisanuki YY, Yanagisawa M, Moriya H, Fukuda Y, Shimoyama M | title = Increased sensitivity to acute and persistent pain in neuron-specific endothelin-1 knockout mice | journal = Neuroscience | volume = 130 | issue = 2 | pages = 349\u201358 | year = 2005 | pmid = 15664691 | doi = 10.1016/j.neuroscience.2004.09.036 }}</ref>\n*[[cardiac hypertrophy]] and [[heart failure]]<ref name=cmls/>\n*[[Dengue haemorrhagic fever]]\n*[[Type II diabetes]]\n*some cases of [[Hirschsprung disease]]\n\nIn [[insulin resistance]] the high levels of blood insulin results in increased production and activity of ET-1, which promotes vasoconstriction and elevates [[blood pressure]].<ref name=\"pmid19491294\">{{cite journal | vauthors = Potenza MA, Addabbo F, Montagnani M | title = Vascular actions of insulin with implications for endothelial dysfunction | journal = American Journal of Physiology. Endocrinology and Metabolism | volume = 297 | issue = 3 | pages = E568-77 | date = September 2009 | pmid = 19491294 | doi = 10.1152/ajpendo.00297.2009 }}</ref>\n\nET-1 impairs glucose uptake in the skeletal muscles of insulin resistant subjects, thereby worsening [[insulin resistance]].<ref name=\"pmid20207830\">{{cite journal | vauthors = Shemyakin A, Salehzadeh F, B\u00f6hm F, Al-Khalili L, Gonon A, Wagner H, Efendic S, Krook A, Pernow J | display-authors = 6 | title = Regulation of glucose uptake by endothelin-1 in human skeletal muscle in vivo and in vitro | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 95 | issue = 5 | pages = 2359\u201366 | date = May 2010 | pmid = 20207830 | doi = 10.1210/jc.2009-1506 }}</ref>\n\nIn preliminary research, injection of endothelin-1 into a [[lateral ventricle|lateral cerebral ventricle]] was shown to potently stimulate [[metabolism|glucose metabolism]] in specified interconnected circuits of the brain, and to induce [[convulsion]]s, indicating its potential for diverse neural effects in conditions such as [[epilepsy]].<ref name=\"chew\">{{cite journal | vauthors = Chew BH, Weaver DF, Gross PM | title = Dose-related potent brain stimulation by the neuropeptide endothelin-1 after intraventricular administration in conscious rats | journal = Pharmacology, Biochemistry, and Behavior | volume = 51 | issue = 1 | pages = 37\u201347 | date = May 1995 | pmid = 7617731 | doi = 10.1016/0091-3057(94)00332-D }}</ref> Receptors for endothelin-1 exist in brain [[neuron]]s, indicating a potential role in neural functions.<ref name=cmls/>\n\n==Antagonists==\nEarliest antagonists discovered for ET<sub>A</sub> were [[BQ123]], and for ET<sub>B</sub>, [[BQ788]].<ref name=mc /> An ET<sub>A</sub>-selective antagonist, [[ambrisentan]] was approved for treatment of [[pulmonary arterial hypertension]] in 2007, followed by a more selective ET<sub>A</sub> antagonist, [[sitaxentan]], which was later withdrawn due to potentially lethal effects in the liver.<ref name=pr/> [[Bosentan]] was a precursor to [[macitentan]], which was approved in 2013.<ref name=pr/>\n\n== References ==\n{{Reflist}}\n\n== External links ==\n* {{MeshName|Endothelins}}\n\n{{Intercellular signaling peptides and proteins}}\n{{Peptidergics}}\n\n[[Category:Peptide hormones]]\n[[Category:Hormones of the blood vessels]]\n", "text_old": "{{Pfam_box \n| Symbol = Endothelin \n| Name = Endothelin family \n| image = 1EDN human endothelin1 02.png\n| width = \n| caption = \n| Pfam= PF00322\n| InterPro= IPR001928\n| SMART= \n| Prosite = PDOC00243\n| SCOP = 1edp\n| TCDB = \n| OPM family= 147\n| OPM protein= 3cmh\n| PDB=   \n}} \n{{infobox protein \n| Name = [[Endothelin 1]] \n| caption = \n| image = | width = \n| HGNCid = 3176 \n| Symbol = [[EDN1]] \n| AltSymbols = \n| EntrezGene = 1906 \n| OMIM = 131240 \n| RefSeq = NM_001955 \n| UniProt = P05305 \n| PDB = \n| ECnumber = \n| Chromosome = 6 \n| Arm = p \n| Band = 23 \n| LocusSupplementaryData = -p24 }}\n{{infobox protein\n| Name = [[Endothelin 2]]\n| image = \n| width = \n| caption =\n| Symbol = [[Endothelin 2|EDN2]]\n| AltSymbols =\n| ATC_prefix=\n| ATC_suffix=\n| ATC_supplemental=\n| CAS_number=\n| CAS_supplemental=\n| DrugBank=\n| EntrezGene = 1907\n| HGNCid =3177\n| OMIM = 131241\n| PDB =\n| RefSeq = NM_001956\n| UniProt = P20800\n| ECnumber = \n| Chromosome = 1\n| Arm = p\n| Band = 34\n| LocusSupplementaryData = \n}}\n{{infobox protein\n| Name = [[Endothelin 3]]\n| image = \n| width = \n| caption =\n| Symbol = [[EDN3]]\n| AltSymbols =\n| ATC_prefix=\n| ATC_suffix=\n| ATC_supplemental=\n| CAS_number=\n| CAS_supplemental=\n| DrugBank=\n| EntrezGene = \n| HGNCid =3178\n| OMIM = 131242\n| PDB =\n| RefSeq = NM_000114\n| UniProt = P14138\n| ECnumber = \n| Chromosome = 20\n| Arm = q\n| Band = 13.2\n| LocusSupplementaryData = -q13.3\n}}\n'''Endothelins''' are peptides with [[receptor (biochemistry)|receptor]]s and effects in many body organs.<ref name=\"pr\">{{cite journal | vauthors = Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ | display-authors = 6 | title = Endothelin | journal = Pharmacological Reviews | volume = 68 | issue = 2 | pages = 357\u2013418 | date = April 2016 | pmid = 26956245 | pmc = 4815360 | doi = 10.1124/pr.115.011833 }}</ref><ref name=\"cmls\">{{cite journal | vauthors = Kawanabe Y, Nauli SM | title = Endothelin | journal = Cellular and Molecular Life Sciences | volume = 68 | issue = 2 | pages = 195\u2013203 | date = January 2011 | pmid = 20848158 | pmc = 3141212 | doi = 10.1007/s00018-010-0518-0 }}</ref><ref name=\"arpt\">{{cite journal | vauthors = Kedzierski RM, Yanagisawa M | title = Endothelin system: the double-edged sword in health and disease | journal = Annual Review of Pharmacology and Toxicology | volume = 41 | pages = 851\u201376 | year = 2001 | pmid = 11264479 | doi = 10.1146/annurev.pharmtox.41.1.851 }}</ref>  Endothelin constricts blood vessels and raises blood pressure. The endothelins are normally kept in balance by other mechanisms, but when [[gene expression|overexpressed]], they contribute to high blood pressure ([[hypertension]]), [[heart disease]], and potentially other diseases.<ref name=pr/><ref>{{cite journal | vauthors = Maguire JJ, Davenport AP | title = Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12 | journal = British Journal of Pharmacology | volume = 171 | issue = 24 | pages = 5555\u201372 | date = December 2014 | pmid = 25131455 | pmc = 4290702 | doi = 10.1111/bph.12874 }}</ref>\n\nEndothelins are 21-[[amino acid]] [[vasoconstriction|vasoconstricting]] [[peptide]]s produced primarily in the [[endothelium]] having a key role in [[smooth muscle|vascular homeostasis]]. Endothelins are implicated in vascular diseases of several organ systems, including the heart, lungs, kidneys, and brain.<ref name=\"pmid11984741\">{{cite journal | vauthors = Agapitov AV, Haynes WG | title = Role of endothelin in cardiovascular disease | journal = Journal of the Renin-Angiotensin-Aldosterone System | volume = 3 | issue = 1 | pages = 1\u201315 | date = March 2002 | pmid = 11984741 | doi = 10.3317/jraas.2002.001 }}</ref><ref name=\"pmid16529555\">{{cite journal | vauthors = Schinelli S | title = Pharmacology and physiopathology of the brain endothelin system: an overview | journal = Current Medicinal Chemistry | volume = 13 | issue = 6 | pages = 627\u201338 | year = 2006 | pmid = 16529555 | doi = 10.2174/092986706776055652 }}</ref> As of 2018, endothelins remain under extensive [[basic research|basic]] and [[clinical research]] to define their roles in several organ systems.<ref name=pr/><ref>{{cite journal | vauthors = Kuang HY, Wu YH, Yi QJ, Tian J, Wu C, Shou WN, Lu TW | title = The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis | journal = Medicine | volume = 97 | issue = 10 | pages = e0075 | date = March 2018 | pmid = 29517668 | pmc = 5882424 | doi = 10.1097/MD.0000000000010075 }}</ref><ref>{{cite journal | vauthors = Iljazi A, Ayata C, Ashina M, Hougaard A | title = The Role of Endothelin in the Pathophysiology of Migraine-a Systematic Review | journal = Current Pain and Headache Reports | volume = 22 | issue = 4 | pages = 27 | date = March 2018 | pmid = 29557064 | doi = 10.1007/s11916-018-0682-8 }}</ref><ref>{{cite journal | vauthors = Lu YP, Hasan AA, Zeng S, Hocher B | title = Plasma ET-1 Concentrations Are Elevated in Pregnant Women with Hypertension -Meta-Analysis of Clinical Studies | journal = Kidney & Blood Pressure Research | volume = 42 | issue = 4 | pages = 654\u2013663 | year = 2017 | pmid = 29212079 | doi = 10.1159/000482004 }}</ref>\n\n==Etymology==\nEndothelins derived the name from their isolation in cultured [[endothelial cell]]s.<ref name=pr/><ref name=mc>{{cite book|first1=Ronald F|last1=Tuma|first2=Walter N|last2=Dur\u00e1n|first3=Klaus|last3=Ley|name-list-format=vanc|title=Microcirculation|year=2008|publisher=Elsevier/Academic Press|location=Amsterdam|isbn=978-0-12-374530-9|pages=[https://archive.org/details/microcirculation0000unse/page/305 305\u2013307]|edition=2nd|url=https://archive.org/details/microcirculation0000unse/page/305}}</ref>\n\n== Isoforms ==\n\nThere are three [[isoform]]s of the peptide (identified as ET-1, -2, -3), each encoded by a seperate gene, with varying regions of expression and binding to at least four known [[endothelin receptor]]s, ET<sub>A</sub>, ET<sub>B1</sub>, ET<sub>B2</sub> and ET<sub>C</sub>.<ref name=pr/><ref name=\"boron\">{{cite book| first1=Walter F. |last1=Boron|first2= Emile L.|last2= Boulpaep | name-list-format = vanc |title=Medical physiology a cellular and molecular approach|year=2009|publisher=Saunders/Elsevier|location=Philadelphia, PA|isbn=978-1-4377-2017-4|pages=480|edition=2nd International}}</ref>\n\nThe human [[gene]]s for endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3) are located on [[chromosome]]s 6, 1, and 20, respectively.<ref name=cmls/>\n\n== Mechanism of action and function ==\n\nEndothelin functions through activation of two [[G protein]]-coupled receptors, endothelin<sub>A</sub> and endothelin<sub>B</sub> receptor (ETA and ETB, respectively).<ref name=cmls/> These two subtypes of endothelin receptor are distinguished in the laboratory by the order of their affinity for the three endothelin peptides: the ETA receptor is selective for ET-1, whereas the ETB receptor has the same affinity for all three ET peptides.<ref name=cmls/> The two types of ET receptor are distributed across diverse cells and [[organ (anatomy)|organs]], but with different levels of expression and activity, indicating a multiple-organ ET system.<ref name=cmls/>\n\nEndothelin-1 is the most powerful [[endogenous]] chemical affecting vascular tone across organ systems.<ref name=cmls/><ref name=\"miy\">{{cite journal | vauthors = Miyauchi T, Sakai S | title = Endothelin and the heart in health and diseases | journal = Peptides | volume = 111 | pages = 77\u201388 | date = January 2019 | pmid = 30352269 | doi = 10.1016/j.peptides.2018.10.002 }}</ref> Secretion of endothelin-1 from the vascular [[endothelium]] signals vasoconstriction and influences local cellular growth and survival.<ref name=miy/>  ET-1 has been implicated in the development and progression of several [[cardiovascular disease]]s, such as [[atherosclerosis]] and [[hypertension]].<ref name=miy/> Endothelin also has roles in [[mitogenesis]], cell survival, [[angiogenesis]], bone growth, [[nociceptor]] function, and cancer onset mechanisms.<ref name=cmls/> Clinically, anti-ET drugs are used to treat [[pulmonary arterial hypertension]].<ref name=cmls/><ref name=miy/>\n\n==Physiological effects==\nEndothelins are the most potent vasoconstrictors known.<ref name=pr/><ref name=craig>{{cite book|first1=Charles R|last1=Craig|first2= Robert E|last2= Stitzel | name-list-format = vanc |title=Modern pharmacology with clinical applications|year=2004|publisher=Lippincott Williams & Wilkins|location=Philadelphia|isbn=978-0-7817-3762-3|pages=215|edition=6th}}</ref> Overproduction of endothelin in the lungs may cause [[pulmonary hypertension]], which was treatable in preliminary research by [[bosentan]], [[sitaxentan]] or [[ambrisentan]].<ref name=pr/>\n\nEndothelins have involvement in cardiovascular function, fluid-[[electrolyte]] [[homeostasis]], and neuronal mechanisms across diverse cell types.<ref name=pr/> Endothelin receptors are present in the three [[pituitary gland|pituitary lobes]]<ref>{{cite journal | vauthors = Lange M, Pagotto U, Renner U, Arzberger T, Oeckler R, Stalla GK | title = The role of endothelins in the regulation of pituitary function | journal = Experimental and Clinical Endocrinology & Diabetes | volume = 110 | issue = 3 | pages = 103\u201312 | date = May 2002 | pmid = 12012269 | doi = 10.1055/s-2002-29086 }}</ref> which display increased metabolic activity when exposed to endothelin-1 in the blood or ventricular system.<ref>{{cite journal | vauthors = Gross PM, Wainman DS, Espinosa FJ | title = Differentiated metabolic stimulation of rat pituitary lobes by peripheral and central endothelin-1 | journal = Endocrinology | volume = 129 | issue = 2 | pages = 1110\u20132 | date = August 1991 | pmid = 1855455 | doi = 10.1210/endo-129-2-1110 }}</ref>\n\nET-1 contributes to the vascular dysfunction associated with cardiovascular disease, particularly [[atherosclerosis]] and [[hypertension]].<ref name=\"pmid17617392\">{{cite journal | vauthors = B\u00f6hm F, Pernow J | title = The importance of endothelin-1 for vascular dysfunction in cardiovascular disease | journal = Cardiovascular Research | volume = 76 | issue = 1 | pages = 8\u201318 | date = October 2007 | pmid = 17617392 | doi = 10.1016/j.cardiores.2007.06.004 | url = https://pdfs.semanticscholar.org/0919/6e83c2860201c9a761b228777799c1c0b8aa.pdf }}</ref> The ET<sub>A</sub> receptor for ET-1 is primarily located on vascular smooth muscle cells, mediating vasoconstriction, whereas the ET<sub>B</sub> receptor for ET-1 is primarily located on endothelial cells, causing vasodilation due to [[nitric oxide]] release.<ref name=\"pmid17617392\" />\n\nThe binding of [[platelet]]s to the [[endothelium|endothelial cell]] receptor [[OLR1|LOX-1]] causes a release of  endothelin, which induces [[endothelial dysfunction]].<ref name=\"pmid10618423 \">{{cite journal | vauthors = Kakutani M, Masaki T, Sawamura T | title = A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 97 | issue = 1 | pages = 360\u20134 | date = January 2000 | pmid = 10618423 | pmc = 26668 | doi = 10.1016/j.biochi.2016.10.010 | bibcode = 2000PNAS...97..360K | url = http://www.pnas.org/content/97/1/360.long }}</ref>\n\n== Clinical significance ==\n\nThe ubiquitous distribution of endothelin peptides and receptors implicates involvement in a wide variety of physiological and pathological processes among different [[organ (anatomy)|organ systems]].<ref name=pr/> Among numerous diseases potentially occurring from endothelin dysregulation are:\n\n* several types of [[cancer]]<ref name=cmls/><ref name=\"pmid18325824\">{{cite journal | vauthors = Bagnato A, Rosan\u00f2 L | title = The endothelin axis in cancer | journal = The International Journal of Biochemistry & Cell Biology | volume = 40 | issue = 8 | pages = 1443\u201351 | year = 2008 | pmid = 18325824 | doi = 10.1016/j.biocel.2008.01.022 }}</ref>\n* [[Cerebrum|cerebral]] [[vasospasm]] following [[subarachnoid hemorrhage]]<ref name=\"pmid17479073\">{{cite journal | vauthors = Macdonald RL, Pluta RM, Zhang JH | title = Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution | journal = Nature Clinical Practice. Neurology | volume = 3 | issue = 5 | pages = 256\u201363 | date = May 2007 | pmid = 17479073 | doi = 10.1038/ncpneuro0490 }}</ref>\n* [[arterial hypertension]], [[pulmonary hypertension]], and other [[cardiovascular]] disorders<ref name=cmls/>\n* [[pain]] mediation<ref name=\"pmid15664691\">{{cite journal | vauthors = Hasue F, Kuwaki T, Kisanuki YY, Yanagisawa M, Moriya H, Fukuda Y, Shimoyama M | title = Increased sensitivity to acute and persistent pain in neuron-specific endothelin-1 knockout mice | journal = Neuroscience | volume = 130 | issue = 2 | pages = 349\u201358 | year = 2005 | pmid = 15664691 | doi = 10.1016/j.neuroscience.2004.09.036 }}</ref>\n*[[cardiac hypertrophy]] and [[heart failure]]<ref name=cmls/>\n*[[Dengue haemorrhagic fever]]\n*[[Type II diabetes]]\n*some cases of [[Hirschsprung disease]]\n\nIn [[insulin resistance]] the high levels of blood insulin results in increased production and activity of ET-1, which promotes vasoconstriction and elevates [[blood pressure]].<ref name=\"pmid19491294\">{{cite journal | vauthors = Potenza MA, Addabbo F, Montagnani M | title = Vascular actions of insulin with implications for endothelial dysfunction | journal = American Journal of Physiology. Endocrinology and Metabolism | volume = 297 | issue = 3 | pages = E568-77 | date = September 2009 | pmid = 19491294 | doi = 10.1152/ajpendo.00297.2009 }}</ref>\n\nET-1 impairs glucose uptake in the skeletal muscles of insulin resistant subjects, thereby worsening [[insulin resistance]].<ref name=\"pmid20207830\">{{cite journal | vauthors = Shemyakin A, Salehzadeh F, B\u00f6hm F, Al-Khalili L, Gonon A, Wagner H, Efendic S, Krook A, Pernow J | display-authors = 6 | title = Regulation of glucose uptake by endothelin-1 in human skeletal muscle in vivo and in vitro | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 95 | issue = 5 | pages = 2359\u201366 | date = May 2010 | pmid = 20207830 | doi = 10.1210/jc.2009-1506 }}</ref>\n\nIn preliminary research, injection of endothelin-1 into a [[lateral ventricle|lateral cerebral ventricle]] was shown to potently stimulate [[metabolism|glucose metabolism]] in specified interconnected circuits of the brain, and to induce [[convulsion]]s, indicating its potential for diverse neural effects in conditions such as [[epilepsy]].<ref name=\"chew\">{{cite journal | vauthors = Chew BH, Weaver DF, Gross PM | title = Dose-related potent brain stimulation by the neuropeptide endothelin-1 after intraventricular administration in conscious rats | journal = Pharmacology, Biochemistry, and Behavior | volume = 51 | issue = 1 | pages = 37\u201347 | date = May 1995 | pmid = 7617731 | doi = 10.1016/0091-3057(94)00332-D }}</ref> Receptors for endothelin-1 exist in brain [[neuron]]s, indicating a potential role in neural functions.<ref name=cmls/>\n\n==Antagonists==\nEarliest antagonists discovered for ET<sub>A</sub> were [[BQ123]], and for ET<sub>B</sub>, [[BQ788]].<ref name=mc /> An ET<sub>A</sub>-selective antagonist, [[ambrisentan]] was approved for treatment of [[pulmonary arterial hypertension]] in 2007, followed by a more selective ET<sub>A</sub> antagonist, [[sitaxentan]], which was later withdrawn due to potentially lethal effects in the liver.<ref name=pr/> [[Bosentan]] was a precursor to [[macitentan]], which was approved in 2013.<ref name=pr/>\n\n== References ==\n{{Reflist}}\n\n== External links ==\n* {{MeshName|Endothelins}}\n\n{{Intercellular signaling peptides and proteins}}\n{{Peptidergics}}\n\n[[Category:Peptide hormones]]\n[[Category:Hormones of the blood vessels]]\n", "name_user": "Jellysandwich0", "label": "safe", "comment": "spelling", "url_page": "//en.wikipedia.org/wiki/Endothelin"}
